Access type

Forgot your password? Click here

DMP_ForgotOK Close


If you are a doctor or a journalist not yet registered at the Dompé reserved areas, click here to fill in the form.


An Italian excellence

Dompé HUB at L'Aquila

Dompé has concentrated its manufacturing and research activities at its Aquila hub.

Established in 1993, it occupies over 30,000 m2 and is now recognised as a centre of excellence both nationally - it is one of the main centres in central-southern Italy - and internationally.

Innovation and technologies in Research & Development

Several different facilities dedicated to the research and development of new synthetic and biotechnological drugs are in operation at the Aquila hub. The hub employees 70 researchers and now, thanks to the special technical and scientific skills it has accumulated over the years, the facility is able to cover the entire Drug Discovery process, from the initial research stages up to final clinical development.

The centre includes a state-of-the-art biotechnology facility designed for seeking out therapeutic solutions in the field of rare diseases and orphan therapies, with authorisation from Italy’s regulatory authorities in accordance with European guidelines.

Below are the facilities dedicated to the research and development of new technologies.


Contract Development and Manufacturing Organization (CDMO)


Biotech Formulation (BF)


Primary Care Formulation (PCF)

Pharmaceutical Production

The Aquila facility is the production site for the main drugs marketed by Dompé in Italy and all around the world.
This non-stop development and implementation facility hosts two production lines dedicated to packets, three lines dedicated to sticks, one line for syrups and one line for dosed vials (drops and sprays).

This is the facility where powders, mouth-dissolvable powders, syrups, mouthwashes, drops, and sprays are produced.

The production lines are constantly being modernised and expanded in order to meet growing demand for products of Italian and international markets and because of the ongoing need to align Dompé production with the latest international standards. Ever since the Company began manufacturing products at its new facility in L’Aquila, it has always been a strategic goal for Dompé to pursue technological innovation in pharmaceutical production.
The latest example of this strategy is the insertion of new powder granulation and “one pot” coating systems, whose introduction allows the Dompé facility in L’Aquila to combine high manufacturing efficiency with the versatility of our production systems.


A constantly developing centre


Industry 4.0: the smart factory